2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, CML, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

5076 Interim report of a hero Consortium study: Real-world evaluation of treatments and outcomes among adult AYAs with Philadelphia chromosome-negative acute lymphoblastic leukemia

Caitlin R Rausch, PharmD, BCOP, Shawn Griffin, PharmD2, Lydia L Benitez, PharmD, BCOP3, Brigid Rowell, MA4, Jeffrey Baron, PharmD5, Callee Brooks6, Adam Dipippo, PharmD7, Thu Doan, PharmD8, Julie Guglielmo, PharmD9, Hailey Hirata, PharmD10, Taylor Kujawa, PharmD11, Heena Kurish, PharmD12, Sara Leidy, PharmD13, Mimi Lo, PharmD, BCPS, BCOP14, Bernard Lawrence Marini Jr, PharmD, BCOP, FHOPA15, Kayleigh Marx, PharmD16, Benjamin Moskoff, PharmD17, Benyam Muluneh, PharmD18, Matthew J. Newman, PharmD, MEHP, BCOP19, Anthony John Perissinotti, PharmD, BCOP20, Sarah Profitt, PharmD21, Ila Saunders22, Matthew John Savas, PharmD23, Jordan Snyder, PharmD, BCOP24, Ashley Soule25, Jennifer K Tobin, PharmD26, Justin Tossey, PharmD27, Emma Uchida28, Allyson Waller, PharmD, BCOP29, Charlotte Burton Wagner, PharmD30, Matthew Warrick, PharmD, BCPS, BCOP31, Kyle Zacholski32, Benjamin J. Lee, PharmD33
1 MD Anderson Cancer Center, Houston, Texas, United States
2 University of California-Irvine, Irvine, California, United States
3 University of Michigan, Ann Arbor, Michigan, United States
4 University of Michigan, Ann Arbor, Michigan, United States
5 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
6 Vanderbilt University Medical Center, Nashville, Tennessee, United States
7 MD Anderson Cancer Center, Houston, Texas, United States
8 University of California San Diego, La Jolla, California, United States
9 University of California, Davis, Sacramento, California, United States
10 University of North Carolina, Chapel Hill, North Carolina, United States
11 University of Utah Huntsman Center, Salt Lake City, Utah, United States
12 Cleveland Clinic, Cleveland, Ohio, United States
13 University of Kansas Health System, Westwood, Kansas, United States
14 University of California San Francisco, San Francisco, California, United States
15 University of Michigan, Ann Arbor, Michigan, United States
16 MD Anderson Cancer Center, Houston, Texas, United States
17 University of California, Davis, Sacramento, California, United States
18 University of North Carolina, Chapel Hill, North Carolina, United States
19 Johns Hopkins Hospital, Baltimore, Maryland, United States
20 University of Michigan, Ann Arbor, Michigan, United States
21 Vanderbilt University Medical Center, Nashville, Tennessee, United States
22 University of California San Diego, La Jolla, California, United States
23 University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah, United States
24 University of Kansas Health System, Westwood, Kansas, United States
25 University of Kentucky, Lexington, Kentucky, United States
26 University of Colorado, Aurora, Colorado, United States
27 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
28 University of Kentucky, Lexington, Kentucky, United States
29 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
30 University of Colorado, Aurora, Colorado, United States
31 Medical University of South Carolina, Charleston, South Carolina, United States
32 Virginia Commonwealth University Health, Richmond, Virginia, United States
33 University of California-Irvine, Irvine, California, United States

Introduction: Adult adolescent and young adults (AYAs; 18-39 years) with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) represent a unique subset of patients due to a high rate of adverse risk genomics and the lack of standardized treatment approach throughout the United States (US). Over the past decade, the treatment landscape for this patient population has shifted to asparaginase-based regimens (ABR) with novel adjunct therapies. The purpose of this study was to characterize real-world treatment utilization and outcomes in adult AYAs treated in the US.

Methods: This was a multicenter, retrospective review conducted by 18 US centers participating in the Hematology Research & Outcomes (HERO) Consortium. Adult AYAs with newly diagnosed Ph- B-ALL or T-ALL who initiated treatment with either Hyper-CVAD (HCVAD) or ABRs between January 2018—June 2024 were assessed for inclusion. Demographic, disease-related and treatment characteristics, as well as outcomes were abstracted from the medical record. Treatment modifications were defined as any change in chemotherapy dose or administration day compared to the standard regimen. -risk disease was defined according to NCCN (B-ALL) and as absence of NOTCH1 and/or FBXW7 or presence of RAS/PTEN alterations (T-ALL). Frontline use of blinatumomab, inotuzumab, nelarabine, or venetoclax was categorized as adjunct therapy. The primary endpoint was event-free survival (EFS) defined as failure to achieve hematologic response (bone marrow blasts <5% with no extramedullary disease) following induction, relapse, or death. Secondary endpoints included hematologic response, measurable residual disease (MRD) negativity, overall survival (OS), and cumulative incidence of relapse (CIR), treating death or allogeneic stem cell transplantation (SCT) as competing risks. Time-to-event endpoints were summarized via the Kaplan-Meier method.

Results: A total of 274 patients were included; 42 (15%) received HCVAD and 232 (85%) received ABR. Two hundred (73%) patients had B-ALL, median age was 26 (range, 18-29) years, 179 (65%) were male, and 86 (31%) were Hispanic. Among those with B-ALL, 120 (60%) had known high-risk disease with 51 (26%) having Ph-like subtype. Twenty-four (32%) patients with T-ALL had known high-risk disease with 22 (30%) having the ETP-subtype. Among the 232 patients treated with ABR, 175 (75%) received CALGB10403/modified CALGB10403, 19 (8%) B-ALL COG protocols (AALL1131, AALL1731, AALL1732), 19 (8%) adult protocols (ECOG1910, modified Linker, modified BFM), 18 (8%) COG T-ALL protocols (AALL1231, AALL0434), and 1 (0.4%) COG B/T-ALL protocol.

Adjunct therapy was utilized in 68 (25%) patients overall, including 27 (64%) treated with HCVAD and 41 (18%) treated with ABR. Among the 200 patients with B-ALL, 53 (27%) received blinatumomab, including 25 (69%) with HCVAD and 28 (17%) with ABR. Blinatumomab was administered at a median of 3.2 months after treatment initiation for a median of 2 (range, 1-5) cycles. Seven (13%) patients received blinatumomab during induction, 24 (45%) in the MRD-negative setting, 18 (34%) for MRD-positivity, and 4 (8%) with an unknown MRD status. Fifteen (8%) patients treated with HCVAD and 3 (2%) with ABR received inotuzumab at a median of 1 month after treatment initiation for a median of 3 (range, 2-4) cycles, for a total median dose of 2.1 mg/m2. Among the 74 patients with T-ALL, 10 (14%) received nelarabine with ABR and 2 (3%) received venetoclax with HCVAD.

Of the 266 evaluable patients, 90% achieved a hematologic response (73% complete response) and 56% achieved MRD-negativity by flow cytometry after induction. Eighty-seven patients (32%) proceeded to SCT in first complete response (CR1). Median follow up was 3.7 years. The estimated 3-year EFS and OS among the B-ALL subgroup was 58% and 81%, respectively. The estimated 3-year EFS and OS among the T-ALL subgroup was 67% and 76%, respectively. CIR at 3-years was 27% (95% CI, 20.3%-34.1%) among those with B-ALL and 21% (95% CI, 11.1%-32.5%) among those with T-ALL.

 Conclusion: This real-world multicenter analysis of adult AYAs with Ph- ALL demonstrates a heterogenous approach to treatment. ABRs, in particular the CALGB10403 regimen or modified versions, are most frequently utilized in the frontline setting. Adjunct therapy is common, predominantly in patients receiving HCVAD, and most often incorporates blinatumomab. A comprehensive toxicity and efficacy analysis is ongoing.

Caitlin R Rausch, PharmD, BCOP: Johnson and Johnson - Consultancy (Includes expert testimony)